Marker Therapeutics, Inc.
MRKR
$1.21
-$0.07-5.47%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -51.00% | -35.99% | -26.34% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -51.00% | -35.99% | -26.34% |
| Cost of Revenue | -64.66% | -9.34% | -57.91% | -32.42% | 78.86% |
| Gross Profit | 64.66% | 9.34% | 63.40% | 27.98% | -258.18% |
| SG&A Expenses | 21.05% | -10.18% | -17.57% | 19.78% | -17.23% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.84% | -9.59% | -51.13% | -22.10% | 47.30% |
| Operating Income | 48.84% | 9.59% | 51.21% | 10.97% | -121.92% |
| Income Before Tax | 54.52% | 28.49% | 54.63% | 13.41% | -83.13% |
| Income Tax Expenses | -- | -- | -130.40% | -- | -- |
| Earnings from Continuing Operations | 54.52% | 28.49% | 55.62% | 13.41% | -83.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 54.52% | 28.49% | 55.62% | 13.41% | -83.13% |
| EBIT | 48.84% | 9.59% | 51.21% | 10.97% | -121.92% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 67.12% | 58.88% | 78.96% | 53.88% | -17.00% |
| Normalized Basic EPS | 67.13% | 54.21% | 78.48% | 53.93% | -16.98% |
| EPS Diluted | 67.38% | 58.88% | 78.96% | 53.85% | -16.00% |
| Normalized Diluted EPS | 67.13% | 54.21% | 78.48% | 53.93% | -16.98% |
| Average Basic Shares Outstanding | 38.39% | 73.91% | 110.94% | 87.80% | 56.50% |
| Average Diluted Shares Outstanding | 38.39% | 73.91% | 110.94% | 87.80% | 56.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |